Trial results

$KYMR — KT-621

Kymera Therapeutics, Inc. (KYMR) KT-621: trial results in Atopic dermatitis, 2026.

Research by Catalyst Intel

The catalyst

"The Company plans to report topline data by year-end 2026."

— Kymera Therapeutics, 8-K filed 2026-10-29 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

KYMR-KT621-2026

Company

Kymera Therapeutics, Inc.

Kind

Trial results

Indication

Atopic dermatitis

Window

2026-01-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.